Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 2/20 | 0.67 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | CA1 | P00915 | 1/20 | 0.62 |
| ▸ | CA2 | P00918 | 1/20 | 0.62 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.62 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.62 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.62 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.59 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.59 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2329138 | 1.00 | KLK7 (0.67) | KLK7KLK5MAPTCA1CA2 | |
| SCHEMBL2329143 | 1.00 | KLK7 (0.67) | KLK7KLK5MAPTCA1CA2 | |
| SCHEMBL14014416 | 0.97 | KLK7 (0.63) | KLK7KLK5MAPTCA1CA2 | |
| SCHEMBL13120843 | 0.97 | KLK7 (0.63) | KLK7KLK5MAPTCA1CA2 | |
| SCHEMBL7323841 | 0.96 | KLK7 (0.63) | KLK7KLK5MAPTCA1CA2 | |
| SCHEMBL13430768 | 0.96 | SIRT2 (0.64) | KLK7KLK5MAPTCA1CA2 | |
| SCHEMBL30043940 | 0.96 | SIRT2 (0.64) | KLK7KLK5MAPTCA1CA2 | |
| SCHEMBL1303931 | 0.94 | MAPT (0.68) | KLK7KLK5MAPTITGB3ITGA2B | |
| SCHEMBL17309872 | 0.94 | MAPT (0.68) | KLK7KLK5MAPTITGB3ITGA2B | |
| SCHEMBL10873871 | 0.94 | KLK7 (0.67) | KLK7KLK5MAPTCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230165932-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165932-A1 | PCSK9 ANTAGONIST COMPOUNDS | PCSK9, PCSK7, PCSK6 | KLK7 194/4885KLK5 77/4885MAPT 2411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.